Instil Bio (TIL) Liabilities and Shareholders Equity (2020 - 2026)

Instil Bio's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $200.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 15.59% year-over-year to $200.4 million; the TTM figure through Mar 2026 stood at $846.7 million (down 20.71% YoY), while the FY2025 annual figure was $203.5 million, down 22.78% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $200.4 million, down from $203.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $568.5 million in Q2 2022, with the low at $200.4 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $306.3 million (2024), against an average of $345.3 million.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity decreased 15.48% in 2022, then slumped 36.13% in 2023.
• Instil Bio's Liabilities and Shareholders Equity stood at $482.1 million in 2022, then tumbled by 32.46% to $325.6 million in 2023, then declined by 19.06% to $263.6 million in 2024, then dropped by 22.78% to $203.5 million in 2025, then declined by 1.52% to $200.4 million in 2026.
• Business Quant data shows TIL's Liabilities and Shareholders Equity at $200.4 million in Q1 2026, $203.5 million in Q4 2025, and $211.8 million in Q3 2025.